NZ703148A - Modified factor x polypeptides and uses thereof - Google Patents
Modified factor x polypeptides and uses thereofInfo
- Publication number
- NZ703148A NZ703148A NZ703148A NZ70314813A NZ703148A NZ 703148 A NZ703148 A NZ 703148A NZ 703148 A NZ703148 A NZ 703148A NZ 70314813 A NZ70314813 A NZ 70314813A NZ 703148 A NZ703148 A NZ 703148A
- Authority
- NZ
- New Zealand
- Prior art keywords
- factor
- polypeptides
- modified
- amino acid
- modified factor
- Prior art date
Links
- 101710136524 X polypeptide Proteins 0.000 title 1
- 108010014173 Factor X Proteins 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 108090000317 Chymotrypsin Proteins 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229960002376 chymotrypsin Drugs 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261741806P | 2012-07-25 | 2012-07-25 | |
| PCT/US2013/032616 WO2014018120A1 (en) | 2012-07-25 | 2013-03-15 | Modified factor x polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ703148A true NZ703148A (en) | 2016-08-26 |
Family
ID=48040462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ703148A NZ703148A (en) | 2012-07-25 | 2013-03-15 | Modified factor x polypeptides and uses thereof |
Country Status (17)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005244271B2 (en) | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
| EP1940457B1 (en) | 2005-10-21 | 2012-12-12 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| CN103289980A (zh) | 2006-07-05 | 2013-09-11 | 催化剂生物科学公司 | 蛋白酶筛选方法及由此鉴别的蛋白酶 |
| SG174077A1 (en) * | 2007-04-13 | 2011-09-29 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| CA2879785C (en) | 2012-07-25 | 2019-06-18 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
| WO2015044836A1 (en) | 2013-09-24 | 2015-04-02 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
| KR20210008177A (ko) * | 2014-01-24 | 2021-01-20 | 화이자 인코포레이티드 | 뇌내 출혈을 치료하기 위한 조성물 및 방법 |
| US10444715B2 (en) * | 2014-05-01 | 2019-10-15 | Belkin International, Inc. | Controlling settings and attributes related to operation of devices in a network |
| DK3149163T3 (da) * | 2014-05-26 | 2020-08-31 | Academisch Ziekenhuis Leiden | Prohæmostatiske proteiner til behandling af blødning |
| US10676730B2 (en) | 2015-01-07 | 2020-06-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Mutated factor X polypeptides and uses thereof for the treatment of haemophilia |
| EP3328998A1 (en) | 2015-07-27 | 2018-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated factor x polypeptides and uses thereof for the treatment of haemophilia |
| AU2017205364B2 (en) * | 2016-01-07 | 2021-03-04 | Eio Biomedical Ltd | Methods, compositions and kits for reducing tissue adhesions |
| FR3050992A1 (fr) * | 2016-05-06 | 2017-11-10 | Lab Francais Du Fractionnement | Mutants du facteur x |
| FR3077296A1 (fr) * | 2018-02-01 | 2019-08-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Dimeres de variants du facteur x |
| WO2019201868A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Coagulation factor based fusion protein with half-life extending polypeptide |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| EP3831843A1 (en) * | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
| WO2023086388A1 (en) * | 2021-11-09 | 2023-05-19 | YewSavin, Inc. | Compositions and methods for treating bleeding and bleeding disorders |
| CN115725594B (zh) * | 2022-03-03 | 2024-11-08 | 南京医科大学 | Pipiserpin蛋白在蚊媒种群控制中的应用 |
| CN114681597A (zh) * | 2022-03-11 | 2022-07-01 | 兆科药业（合肥）有限公司 | 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用 |
| CN116426510B (zh) * | 2023-06-13 | 2023-09-22 | 北京沃森赛瑟生物技术有限公司 | 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4501731A (en) * | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| US5583107A (en) * | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AU6673898A (en) | 1997-03-07 | 1998-09-22 | Washington University | Factor x variant |
| US20030207402A1 (en) | 1997-08-22 | 2003-11-06 | Erhard Kopetzki | Autocatalytically activatable zymogenic precursors of proteases and their use |
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
| US20030186329A1 (en) | 1999-03-22 | 2003-10-02 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| WO2001032711A2 (en) | 1999-10-21 | 2001-05-10 | Board Of Trustees Of The University Of Arkansas | Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
| US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| AU2002230390A1 (en) | 2000-10-05 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
| JP2005518332A (ja) | 2001-05-23 | 2005-06-23 | デンドレオン コーポレイション | 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 |
| AU2002315525A1 (en) | 2001-07-03 | 2003-01-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
| AU2002347858A1 (en) | 2001-10-09 | 2003-04-22 | Dendreon Corporation | Transmembrane serine protease 25 |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| AU2002357004A1 (en) | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| WO2004005471A2 (en) | 2002-07-02 | 2004-01-15 | Dendreon Corporation | Serine protease 16 |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| MXPA05003493A (es) | 2002-10-02 | 2005-09-30 | Catalyst Biosciences | Metodos para generar y seleccionar proteasas con especificidad alterada. |
| WO2005022330A2 (en) | 2003-08-27 | 2005-03-10 | Jambo Networks, Inc. | A system and method for providing communication services to mobile device users |
| WO2005023308A1 (en) | 2003-09-05 | 2005-03-17 | Maxygen Holdings Ltd. | Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
| DE10350880A1 (de) | 2003-10-31 | 2005-06-02 | Roche Diagnostics Gmbh | Verfahren zur Bestimmung eines Analyten mittels einer Extraktionsschicht |
| AU2005244271B2 (en) | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
| US20060029590A1 (en) | 2004-06-10 | 2006-02-09 | Christopher Thanos | Administration of neutral endopeptidase to treat inflammatory bowel disease |
| CA2601574C (en) | 2005-03-15 | 2014-12-02 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| EP1726643A1 (en) | 2005-05-27 | 2006-11-29 | Direvo Biotech AG | Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| EP1940457B1 (en) | 2005-10-21 | 2012-12-12 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| WO2007149406A2 (en) | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
| CN103289980A (zh) | 2006-07-05 | 2013-09-11 | 催化剂生物科学公司 | 蛋白酶筛选方法及由此鉴别的蛋白酶 |
| SG174077A1 (en) | 2007-04-13 | 2011-09-29 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US8268783B2 (en) | 2007-09-28 | 2012-09-18 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same |
| EP3078743B1 (en) | 2007-09-28 | 2020-06-24 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| EP2202306B1 (en) | 2007-10-09 | 2012-12-19 | The Chemo-Sero-Therapeutic Research Institute | Recombinant factor x with no glycosylation and method for preparing the same |
| WO2009098492A2 (en) | 2008-02-07 | 2009-08-13 | Andrew Baker | Modulation of adenoviral tropism |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| WO2009130198A2 (en) * | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| EP3581650B1 (en) | 2008-09-15 | 2022-12-28 | uniQure biopharma B.V. | Factor ix polypeptide mutant, its uses and a method for its production |
| EP2364165B1 (en) | 2008-11-14 | 2018-01-03 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| WO2013049804A1 (en) | 2011-09-30 | 2013-04-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
| CA2879785C (en) | 2012-07-25 | 2019-06-18 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
-
2013
- 2013-03-15 CA CA2879785A patent/CA2879785C/en not_active Expired - Fee Related
- 2013-03-15 WO PCT/US2013/032616 patent/WO2014018120A1/en active Application Filing
- 2013-03-15 MX MX2015001083A patent/MX365612B/es active IP Right Grant
- 2013-03-15 CN CN201380049692.2A patent/CN104755492A/zh active Pending
- 2013-03-15 ES ES13713325T patent/ES2704083T3/es active Active
- 2013-03-15 EA EA201500172A patent/EA028865B1/ru not_active IP Right Cessation
- 2013-03-15 AU AU2013293573A patent/AU2013293573B2/en not_active Ceased
- 2013-03-15 US US13/815,768 patent/US9145552B2/en not_active Expired - Fee Related
- 2013-03-15 JP JP2015524250A patent/JP6363600B2/ja not_active Expired - Fee Related
- 2013-03-15 EP EP13713325.2A patent/EP2877487B1/en active Active
- 2013-03-15 NZ NZ703148A patent/NZ703148A/en not_active IP Right Cessation
- 2013-03-15 SG SG11201500579SA patent/SG11201500579SA/en unknown
- 2013-03-15 IN IN1404DEN2015 patent/IN2015DN01404A/en unknown
- 2013-03-15 BR BR112015001628A patent/BR112015001628A2/pt not_active IP Right Cessation
- 2013-03-15 KR KR1020157004694A patent/KR102049900B1/ko not_active Expired - Fee Related
-
2014
- 2014-04-03 US US14/244,840 patent/US9856467B2/en active Active
- 2014-12-25 IL IL236449A patent/IL236449B/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00097A patent/ZA201500097B/en unknown
-
2018
- 2018-06-28 JP JP2018123235A patent/JP2018183147A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2879785C (en) | 2019-06-18 |
| JP6363600B2 (ja) | 2018-07-25 |
| CN104755492A (zh) | 2015-07-01 |
| IL236449B (en) | 2019-02-28 |
| SG11201500579SA (en) | 2015-02-27 |
| IN2015DN01404A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-03 |
| EA201500172A1 (ru) | 2015-09-30 |
| JP2015524801A (ja) | 2015-08-27 |
| CA2879785A1 (en) | 2014-01-30 |
| IL236449A0 (en) | 2015-02-26 |
| AU2013293573A1 (en) | 2015-02-05 |
| MX365612B (es) | 2019-06-07 |
| EP2877487B1 (en) | 2018-10-17 |
| ZA201500097B (en) | 2016-09-28 |
| US20140030247A1 (en) | 2014-01-30 |
| WO2014018120A1 (en) | 2014-01-30 |
| JP2018183147A (ja) | 2018-11-22 |
| ES2704083T3 (es) | 2019-03-14 |
| BR112015001628A2 (pt) | 2017-11-07 |
| MX2015001083A (es) | 2015-04-08 |
| EP2877487A1 (en) | 2015-06-03 |
| HK1210790A1 (en) | 2016-05-06 |
| KR20160073937A (ko) | 2016-06-27 |
| EA028865B1 (ru) | 2018-01-31 |
| US9856467B2 (en) | 2018-01-02 |
| US9145552B2 (en) | 2015-09-29 |
| KR102049900B1 (ko) | 2019-11-28 |
| AU2013293573B2 (en) | 2016-10-27 |
| US20140234290A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ703148A (en) | Modified factor x polypeptides and uses thereof | |
| MX2016012044A (es) | Serina proteasas de especies de bacillus. | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| MX338925B (es) | Composiciones y metodos que comprenden variantes de proteasa serina. | |
| MX2019003616A (es) | Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas. | |
| EA201691558A1 (ru) | Удаление сериновых протеаз путем обработки тонкоизмельченным диоксидом кремния | |
| MX2012001346A (es) | Polipeptidos del factor ix modificados y usos de los mismos. | |
| PH12015501983A1 (en) | Peptides and compositions for treatment of joint damage | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| IN2012DN00801A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX357941B (es) | Serpinas modificadas para el tratamiento de trastornos de la coagulacion. | |
| MX383346B (es) | Composiciones y metodos que comprenden variantes de serina proteasa. | |
| EA201492177A1 (ru) | Очистка идуронат-2-сульфатазы | |
| MY156851A (en) | Azeotropic and azeotrope-like compositions of methyl perfluoroheptene ethers and trans-1,2-dichloroethylene and uses thereof | |
| MX2019006425A (es) | Estabilizacion de enzimas en composiciones. | |
| MX379863B (es) | Composiciones y metodos relacionados con una toxina mutante de clostridium difficile | |
| PH12014502763A1 (en) | Method for the degradation of keratin and use of the keratin hydrolysate produced | |
| MX2025002623A (es) | Composiciones que comprenden arng y sus usos en el tratamiento de la deficiencia de alfa-1 antitripsina | |
| MX2010002769A (es) | Preparacion recombinante de fracciones de bromelaina seleccionadas. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2017007554A (es) | Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa. | |
| MX2016012428A (es) | Aumento de la expresion de proteina recombinante con cobre. | |
| MX341733B (es) | Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular. | |
| MY178484A (en) | A method for controling proteolytic degradation of recombinant proteins | |
| CL2009000592A1 (es) | Compuestos derivados de piridazina, inhibidores del factor xia y/o calicreina plasmatica; composicion farmaceutica; y uso para el tratamiento o profilaxis de un trastorno tromboembolico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20170228 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2019 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20180305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20190301 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20200303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20210224 |
|
| LAPS | Patent lapsed |